Entry into the Healthcare IoT Business and Partnership with Ascella Biosystems
First written in FY2021-Q2. 4 of 9 entries say "Advanced", first in FY2021-Q3. Latest entry: 2026-09-17.
No other company in this theme has enough history to compare yet.
- 2026-09-17ReframedOccurring Fact
「At the Board of Directors meeting held on 17 September 2026, we resolved to dissolve Axel Medica Co., Ltd., our wholly owned subsidiary, and liquidate it through special liquidation proceedings, while the Company would take over and restructure the beauty and wellness business previously operated by that company.」
The operating structure for the healthcare-related business pursued through Axel Medica was reorganized from operation by the subsidiary to takeover and restructuring by the Company. - FY2025-H1AdvancedAnnual report
「In addition, the company has obtained a Class II medical device marketing license and an in vitro diagnostic pharmaceutical marketing license, completing the framework for its healthcare business, including the required certifications.」
For the healthcare business, the company established an operating framework through its wholly owned subsidiary アクセルメディカ and progressed to obtaining a Class II medical device marketing license and an in vitro diagnostic pharmaceutical marketing license. It continues to work toward the early commercialization of an infectious disease platform using AscellaOne. - FY2024AdvancedAnnual report
「To achieve more flexible and faster business development, the company established its wholly owned subsidiary アクセルメディカ株式会社 as the operating company for the healthcare business and is applying through that company for a Class II medical device marketing authorization and other approvals.」
As the execution structure for the healthcare business, the company established its wholly owned subsidiary アクセルメディカ in September 2024 and proceeded with applications by that company for a Class II medical device marketing authorization and other approvals. - FY2024-Q2ReframedAnnual report
「The company resolved to terminate the basic agreement because it determined that it would be more rational to obtain a Class II medical device marketing authorization itself and promote the healthcare business.」
In the healthcare business, while proceeding with the appointment of a representative director and president of the Japanese entity established by Ascella Biosystems, Inc. and recruiting specialized personnel, the company terminated the basic agreement for acquiring all shares of ABC JAPAN on 30 April 2024 and changed the implementation approach from making ABC JAPAN a subsidiary to promoting the business itself after obtaining a Class II medical device marketing authorization. - FY2024-Q1AdvancedAnnual report
「In the healthcare business, the company aims to secure control of Ascella Biosystems, Inc. together with ウィズ・パートナーズ株式会社, the managing partner of the company's major shareholders ウィズAIoTエボリューション ファンド投資事業有限責任組合 and THEケンコウFUTURE投資事業有限責任組合, and to commercialize Ascella Real Time System at an early stage as its initial initiative. The company believes that making ABC JAPAN a wholly owned subsidiary would enable it to develop a highly profitable healthcare business using Ascella Real Time System, which Ascella Biosystems, Inc. is developing and for which the company holds exclusive manufacturing and sales rights in Japan.」
The company secured control of Ascella Biosystems, Inc. together with its major shareholders and advanced to the stage of seeking early commercialization of Ascella Real Time System. It also planned to develop a healthcare business, including domestic manufacturing and sales using the system, by making ABC JAPAN a wholly owned subsidiary. - FY2022Discussions continue amid delays in fundraisingAnnual report
「Even after the COVID-19 pandemic subsides, this initiative will be capable of addressing various infectious diseases, including COVID-19 variants, and demand is expected in a range of applications because results can be obtained inexpensively and quickly. Accordingly, we will continue discussions toward realizing the initiative even after recording the extraordinary loss this time.」
The company explains that, even after recording an extraordinary loss due to delays in Ascella's fundraising, it will continue discussions toward realizing rapid diagnostic methods. - FY2021RestatedAnnual report
「In the IoT healthcare business, we will focus on initiatives with medical device startup AscellaBiosystems, Inc., in which we have invested and with which we have a business alliance, and which aims to commercialize at an early stage rapid diagnostic methods using molecular diagnostic technology for COVID-19 and other infectious diseases.」
The company continued its medium- to long-term strategy of investing in and forming a business alliance with Ascella Biosystems, Inc. and focusing on an IoT healthcare business using molecular diagnostic technology during the fiscal year. - FY2021-Q3AdvancedAnnual report
「The company will enter into an agreement under which it will be granted exclusive rights, with sublicensing rights, in Japan to use, import, manufacture, sell and outsource the sale of the molecular diagnostic kit "Ascella Real Time System," which Ascella is developing.」
The disclosure describes the business and capital alliance entered into with Ascella Biosystems, Inc. on 22 April 2021, under which the company obtained exclusive rights, with sublicensing rights, in Japan to use, import, manufacture and sell Ascella Real Time System, among other rights. - FY2021-Q2First statedAnnual report
「At a meeting of the Board of Directors held on 22 April 2021, the company resolved to launch a healthcare business as a new business and to invest in and enter into a business alliance with medical device startup Ascella Biosystems, Inc.」
The company aims to create revenue-generating businesses outside advertising, using its IoT expertise and smartphone app development capabilities in healthcare IoT, molecular diagnostic equipment and services that display diagnostic results in smartphone apps. The disclosure states that the business was scheduled to launch in May 2021.